In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

DMD In The Spotlight

Executive Summary

The FDA draft guidance for Duchenne’s muscular dystrophy drug development, which advocacy groups tried to push through to make sure the agency understood the complications of getting some of these drugs approved, is a good example of stakeholder interaction in the rare disease space.

Advertisement

Related Content

Orphans Should Live Alone
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Topics

Related Companies

UsernamePublicRestriction

Register

IV004468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel